IRHYTHM TECHNOLOGIES INC (IRTC)

US4500561067 - Common Stock

116  +0.24 (+0.21%)

After market: 116 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IRTC. IRTC was compared to 196 industry peers in the Health Care Equipment & Supplies industry. The financial health of IRTC is average, but there are quite some concerns on its profitability. IRTC is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year IRTC has reported negative net income.
IRTC had a negative operating cash flow in the past year.
In the past 5 years IRTC always reported negative net income.
In the past 5 years IRTC always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -28.49%, IRTC is in line with its industry, outperforming 44.90% of the companies in the same industry.
Looking at the Return On Equity, with a value of -58.73%, IRTC is in line with its industry, outperforming 41.84% of the companies in the same industry.
Industry RankSector Rank
ROA -28.49%
ROE -58.73%
ROIC N/A
ROA(3y)-25.44%
ROA(5y)-20.54%
ROE(3y)-47.82%
ROE(5y)-39.32%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 67.36%, IRTC is doing good in the industry, outperforming 76.02% of the companies in the same industry.
In the last couple of years the Gross Margin of IRTC has declined.
The Profit Margin and Operating Margin are not available for IRTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.87%
GM growth 5Y-1.78%

4

2. Health

2.1 Basic Checks

IRTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRTC has more shares outstanding than it did 1 year ago.
IRTC has more shares outstanding than it did 5 years ago.
IRTC has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 8.18 indicates that IRTC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.18, IRTC belongs to the top of the industry, outperforming 86.22% of the companies in the same industry.
A Debt/Equity ratio of 0.17 indicates that IRTC is not too dependend on debt financing.
IRTC has a Debt to Equity ratio (0.17) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 8.18
ROIC/WACCN/A
WACC9.41%

2.3 Liquidity

IRTC has a Current Ratio of 2.15. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IRTC (2.15) is worse than 71.43% of its industry peers.
IRTC has a Quick Ratio of 2.02. This indicates that IRTC is financially healthy and has no problem in meeting its short term obligations.
IRTC has a Quick ratio of 2.02. This is comparable to the rest of the industry: IRTC outperforms 42.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 2.02

6

3. Growth

3.1 Past

The earnings per share for IRTC have decreased strongly by -33.10% in the last year.
Looking at the last year, IRTC shows a quite strong growth in Revenue. The Revenue has grown by 19.86% in the last year.
IRTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.31% yearly.
EPS 1Y (TTM)-33.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-88.06%
Revenue 1Y (TTM)19.86%
Revenue growth 3Y22.93%
Revenue growth 5Y27.31%
Revenue growth Q2Q17.68%

3.2 Future

The Earnings Per Share is expected to grow by 24.09% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.73% on average over the next years. This is quite good.
EPS Next Y21.77%
EPS Next 2Y24.12%
EPS Next 3Y24.65%
EPS Next 5Y24.09%
Revenue Next Year18.46%
Revenue Next 2Y18.46%
Revenue Next 3Y18.13%
Revenue Next 5Y17.73%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRTC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

IRTC's earnings are expected to grow with 24.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.12%
EPS Next 3Y24.65%

0

5. Dividend

5.1 Amount

IRTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IRHYTHM TECHNOLOGIES INC

NASDAQ:IRTC (3/28/2024, 8:18:03 PM)

After market: 116 0 (0%)

116

+0.24 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.59B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.49%
ROE -58.73%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 67.36%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.15
Quick Ratio 2.02
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-33.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.86%
Revenue growth 3Y22.93%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y